-Bloomberg
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $16 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $16 price target.
Related Posts
Oppenheimer Maintains Outperform on Roku, Raises Price Target to $75
Oppenheimer analyst Jason Helfstein maintains Roku (NASDAQ:ROKU) with a Outperform and raises the price target from $70 to $75.
DiaMedica Therapeutics Q2 EPS $(0.13) Beats $(0.18) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 23.53 percent increase over losses of $(0.17) per share
Analysts Flip To ‘Outperform’ On Oracle Amid Stock Pullback: ‘Math Is Working In Favor’
Oracle’s recent stock price decline presents an appealing buying opportunity, according to Evercore analysts, who upgraded their rating on…